Patients & Community Acting in the interest of patients

Living with Inherited retinal disease - Maartje de Kok and her family

ProQR is dedicated to developing RNA therapies to improve the lives of patients, families and communities living with inherited retinal diseases, a group of rare diseases causing blindness. To achieve this goal, ProQR strives to integrate the patient voice into our decision-making throughout the drug development process as we believe that a patient-focused strategy is crucial to our success.

Our patient-focused approach

  • We are committed to the communities we serve.
  • We value patients as experts and strive to integrate their insights into our decision-making.
  • We act with a sense of urgency and purpose in the interest of patients.
  • We believe in early, consistent and transparent engagement with the patient community. 

If you have questions or want to stay informed please contact or sign up for our Eye Connect newsletter.

ProQR clinical trials for inherited retinal diseases

Here is a list of all our ongoing clinical trials.
If you are not sure what a clinical trial is all about? Read this first.


Phase 2/3 clinical trial of sepofarsen for CEP290 mediated Leber congenital amaurosis (LCA10).

Read about the Illuminate trial

Illuminate logomark


Phase 1/2 clinical trial of QR-421a for USH2A mediated retinitis pigmentosa and Usher syndrome.

Read about the Stellar trial

Stellar logomark


Phase 1/2 clinical trial of QR-1123 for RHO mediated retinitis pigmentosa.

Read about the Aurora trial

Aurora logomark

How does RNA therapy work?

Learn how the latest RNA technologies can help treat rare genetic diseases